159 related articles for article (PubMed ID: 38195077)
61. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
[No Abstract] [Full Text] [Related]
62. Alectinib relieves ischemic strokes caused by left atrial metastasis in a NSCLC patient with a novel SLC34A2-ALK (exon 1: exon 15) fusion.
Zhou N; Wu M; Yuan M; Wu H; Yu S; Gao X; Wang Y
Lung Cancer; 2023 Sep; 183():107289. PubMed ID: 37542770
[TBL] [Abstract][Full Text] [Related]
63. Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib.
Dziadziuszko R; Peters S; Ruf T; Cardona A; Guerini E; Kurtsikidze N; Smoljanovic V; Planchard D
ESMO Open; 2022 Dec; 7(6):100612. PubMed ID: 36375271
[TBL] [Abstract][Full Text] [Related]
64. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
65. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
Balzer BWR; Loo C; Wegner EA; Nath CE; Lee S; Smith C; Lewis CR; Trahair TN; Anazodo AC
Pediatr Hematol Oncol; 2018; 35(7-8):415-421. PubMed ID: 30526220
[TBL] [Abstract][Full Text] [Related]
66. Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash.
Anderson BE; Luczak TS; Ries LM; Hoefs GE; Silva-Benedict AC
J Oncol Pharm Pract; 2020 Dec; 26(8):2028-2030. PubMed ID: 32476587
[TBL] [Abstract][Full Text] [Related]
67. A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis.
Cheng W; Qian C; Zhang H; Meng Q; Yin JC; Fang S
Anticancer Drugs; 2022 Nov; 33(10):1182-1185. PubMed ID: 35946559
[TBL] [Abstract][Full Text] [Related]
68. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
69. Non-small cell lung cancer patient with a rare UGP2-ALK fusion protein responded well to alectinib: a case report.
Chen L; Chu D; Li W; Zhang H
Anticancer Drugs; 2024 Jan; 35(1):97-100. PubMed ID: 37450292
[TBL] [Abstract][Full Text] [Related]
70. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
71. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
Liu Z; Wu Q; Li W; Li P; Huang L; Wang T; Zhou Q
Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
[TBL] [Abstract][Full Text] [Related]
72. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S
Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886
[TBL] [Abstract][Full Text] [Related]
73. Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports.
Shi L; Gao S; Tong L; Meng Q; Zhou S; Yu D; Dong Y; Liu Z
Front Oncol; 2023; 13():1120511. PubMed ID: 37409244
[TBL] [Abstract][Full Text] [Related]
74. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
[TBL] [Abstract][Full Text] [Related]
75. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
[TBL] [Abstract][Full Text] [Related]
76. Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma-A Case Series.
El Sayed R; Tehfe M; Blais N
Curr Oncol; 2022 Dec; 30(1):518-528. PubMed ID: 36661690
[TBL] [Abstract][Full Text] [Related]
77. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
Ou SI; Nishio M; Ahn MJ; Mok T; Barlesi F; Zhou C; Felip E; de Marinis F; Kim SW; Pérol M; Liu G; Migliorino MR; Kim DW; Novello S; Bearz A; Garrido P; Mazieres J; Morabito A; Lin HM; Yang H; Niu H; Zhang P; Kim ES
J Thorac Oncol; 2022 Dec; 17(12):1404-1414. PubMed ID: 36096442
[TBL] [Abstract][Full Text] [Related]
78. Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy.
Zhai X; Wu Q; Pu D; Yin L; Wang W; Zhu D; Xu F
Front Oncol; 2021; 11():782682. PubMed ID: 35070986
[TBL] [Abstract][Full Text] [Related]
79. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
80. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
